Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1478-811X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer ; volume:15 ; number:1 ; day:8 ; month:12 ; year:2017 ; pages:1-14 ; date:12.2017
Cell communication and signaling ; 15, Heft 1 (8.12.2017), 1-14, 12.2017

Classification
Biowissenschaften, Biologie

Creator
Ferrari, Nicoletta
Contributor
Granata, Ilaria
Capaia, Matteo
Piccirillo, Marina
Guarracino, Mario Rosario
Venè, Roberta
Brizzolara, Antonella
Petretto, Andrea
Inglese, Elvira
Morini, Martina
Astigiano, Simonetta
Amaro, Adriana Agnese
Boccardo, Francesco
Balbi, Cecilia
Barboro, Paola
SpringerLink (Online service)

DOI
10.1186/s12964-017-0206-x
URN
urn:nbn:de:1111-201802094567
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:57 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Ferrari, Nicoletta
  • Granata, Ilaria
  • Capaia, Matteo
  • Piccirillo, Marina
  • Guarracino, Mario Rosario
  • Venè, Roberta
  • Brizzolara, Antonella
  • Petretto, Andrea
  • Inglese, Elvira
  • Morini, Martina
  • Astigiano, Simonetta
  • Amaro, Adriana Agnese
  • Boccardo, Francesco
  • Balbi, Cecilia
  • Barboro, Paola
  • SpringerLink (Online service)

Other Objects (12)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

Androgen deprivation in prostate cancer: benefits of home-based resistance training

Androgen deprivation in prostate cancer: benefits of home-based resistance training

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

PTP1B regulates lymphocytes responses androgen deprivation

PTP1B regulates lymphocytes responses androgen deprivation

Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer

Hochschulschrift

Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer

Related objects